Antigen

About: Antigen is a research topic. Over the lifetime, 170233 publications have been published within this topic receiving 6982342 citations. The topic is also known as: antibody generator & Antigen.

Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

Abstract: The origins of the neoplastic cells in Hodgkin's lymphoma1, the Hodgkin (H) and Sternberg–Reed(SR) cells, are still obscure, and these cells appear to carry no markers found on any population of normal cells2,3. However the recent establishment of permanent Hodgkin cell lines3,4 has led to the search for tumour-specific antigens and/or for membrane markers on H and SR cells which may indicate the normal equivalent cells. Here, we describe the production of mouse monoclonal antibodies against the Hodgkin cell line L428. One hybridoma antibody, Ki-1, was found to be specific for H and SR cells of all Hodgkin's lymphomas tested and a minute, but distinct new cell population in normal tonsils and lymph nodes.

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Abstract: Purpose Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In acute lymphoblastic leukemia (ALL), persistence or relapse of minimal residual disease (MRD) after chemotherapy indicates resistance to chemotherapy and results in hematologic relapse. A phase II clinical study was conducted to determine the efficacy of blinatumomab in MRD-positive B-lineage ALL.

Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy

Abstract: CD4+ T cells classically recognize antigens that are endocytosed and processed in lysosomes for presentation on major histocompatibility complex (MHC) class II molecules. Here, endogenous Epstein-Barr virus nuclear antigen 1 (EBNA1) was found to gain access to this pathway by autophagy. On inhibition of lysosomal acidification, EBNA1, the dominant CD4+ T cell antigen of latent Epstein-Barr virus infection, slowly accumulated in cytosolic autophagosomes. In addition, inhibition of autophagy decreased recognition by EBNA1-specific CD4+ T cell clones. Thus, lysosomal processing after autophagy may contribute to MHC class II-restricted surveillance of long-lived endogenous antigens including nuclear proteins relevant to disease.

Identification of a transformation-specific antigen induced by an avian sarcoma virus.

Abstract: GENETIC analyses of avian sarcoma viruses (ASV) have led to the identification of a gene, designated src, which encodes a product required for the initiation and maintenance of neoplastic transformation in infected fibroblasts1–5. Because the src gene product has not been identified biochemically, this study was initiated to detect a transformation-specific protein, using serum from rabbits bearing ASV-induced tumours. We describe here the identification of a 60,000-MW transformation-specific antigen detectable in ASV-transformed chicken cells and ASV-induced hamster tumour cells by immunoprecipitation of radiolabelled cell extracts with serum from tumour-bearing rabbits. Moreover, the expression of this antigen is temperature dependent in chicken cells transformed by an ASV temperature-sensitive mutant in the src gene. The use of this antiserum may lead to the unequivocal identification and characterisation of the ASV src gene product and this, in turn, may lead to the elucidation of the mechanism of ASV-induced oncogenesis.